Theoretically, some hypoglycemic agents such as glucagon-like peptide-1 receptor agonists (GLP-1RA), dipeptidyl peptidase-4 inhibitors (DPP4i) and a thiazolidinedione (pioglitazone) can improve outcomes in patients with COVID-19 because of their anti-inflammatory effects. Here, GLP1R is linked to COVID-19.